Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HADAR LEV-TOV

Allopathic & Osteopathic Physicians Dermatology

NPI
1174842462
CMS profile
2303701
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$54,777.70

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HADAR LEV-TOV

NPI 1174842462 · CMS profile ID 2303701

Allopathic & Osteopathic Physicians / Dermatology

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174842462?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HADAR LEV-TOV, NPI 1174842462, CMS profile ID 2303701. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174842462?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). HADAR LEV-TOV, NPI 1174842462, CMS profile ID 2303701. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174842462?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
HADAR LEV-TOV, NPI 1174842462, CMS profile ID 2303701, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1174842462?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $54,777.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $9,500.0003/25/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949074899 CMS
Molnlycke Health Care US, LLC $381.9103/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923385003 CMS
Insmed, Inc. $500.0002/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906404001 CMS
KCI USA, Inc. $22.9002/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923502379 CMS
ABBVIE INC. $2,056.0002/22/2022 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893188777 CMS
ABBVIE INC. $514.0002/22/2022 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893188779 CMS
Smith+Nephew, Inc. $18.3902/01/2022 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 960894803 CMS
Molnlycke Health Care US, LLC $1,000.0001/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923384987 CMS
UCB, Inc. $46.0501/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908028523 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,278.35 18
PY2020 $25,041.71 43
PY2021 $40,268.44 17
PY2022 $54,777.70 59
PY2023 $39,113.28 53
PY2024 $57,232.62 68
PY2025 $105,555.29 122

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $225,640.83 127
PY2024 Recipient $4,200.00 3
PY2024 Principal investigator $618,570.30 226
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $242,395.01 171
PY2022 Principal investigator $307,776.14 32
PY2021 Principal investigator $588,559.16 42
PY2020 Recipient $8,413.00 1
PY2020 Principal investigator $75,953.37 10
PY2019 Principal investigator $74,248.54 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

127 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,618.00 12/19/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240480641
Principal investigator 1 Incyte Corporation $1,548.00 12/19/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240480646
Principal investigator 1 Incyte Corporation $1,503.00 12/19/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240480652
Principal investigator 1 Incyte Corporation $2,246.00 12/19/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240480658
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240480663
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240480669
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240480674
Principal investigator 1 Incyte Corporation $1,466.00 12/19/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240480680
Principal investigator 1 UCB SA $2,250.00 12/19/2025 Non-covered Recipient Entity
University Of Miami
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1246656870
Principal investigator 1 Incyte Corporation $5,576.20 12/08/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240608364
Principal investigator 1 Incyte Corporation $806.70 12/04/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240608322
Principal investigator 1 Incyte Corporation $21.33 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240608330
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240608335
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240608340
Principal investigator 1 Incyte Corporation $16.59 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240608343
Principal investigator 1 Incyte Corporation $18.96 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240608353
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240608356
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240608361
Principal investigator 1 Incyte Corporation $766.00 11/24/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240608348
Principal investigator 1 Incyte Corporation $1,174.50 11/13/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240608314
Principal investigator 1 BIOTISSUE HOLDINGS INC. $3,700.00 11/07/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
TTAX01-CR006 No dispute reported 06/30/2026 1246209807
Principal investigator 1 BIOTISSUE HOLDINGS INC. $573.00 11/07/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
TTAX01-CR006 No dispute reported 06/30/2026 1246209809
Principal investigator 1 BIOTISSUE HOLDINGS INC. $367.65 11/07/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
TTAX01-CR006 No dispute reported 06/30/2026 1246209811
Principal investigator 1 BIOTISSUE HOLDINGS INC. $8,670.00 11/07/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
TTAX01-CR006 No dispute reported 06/30/2026 1246209813
Principal investigator 1 BIOTISSUE HOLDINGS INC. $175.00 11/07/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
TTAX01-CR006 No dispute reported 06/30/2026 1246209815
Principal investigator 1 Incyte Corporation $2,349.00 11/06/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240608319
Principal investigator 1 Incyte Corporation $2,235.60 10/20/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240608326
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,720.32 10/08/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190297551
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,689.00 10/01/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190295824
Principal investigator 1 Incyte Corporation $3,736.80 09/23/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240608309
Principal investigator 1 Incyte Corporation $726.00 09/17/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480613
Principal investigator 1 Incyte Corporation $766.00 09/15/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480624
Principal investigator 1 Incyte Corporation $1,987.20 08/20/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480608
Principal investigator 1 Incyte Corporation $2,484.00 08/20/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480635
Principal investigator 1 Incyte Corporation $34.35 08/04/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480618
Principal investigator 1 Incyte Corporation $1,865.70 07/18/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480602
Principal investigator 1 Incyte Corporation $2,484.00 07/18/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480628
Principal investigator 1 Incyte Corporation $1,419.00 06/25/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480507
Principal investigator 1 Incyte Corporation $1,135.20 06/25/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480513
Principal investigator 1 Incyte Corporation $40.17 06/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480526
Principal investigator 1 Incyte Corporation $993.30 05/21/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480558
Principal investigator 1 Incyte Corporation $1,419.00 05/21/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480566
Principal investigator 1 Incyte Corporation $1,419.00 05/21/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480570
Principal investigator 1 Incyte Corporation $1,277.10 05/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480520
Principal investigator 1 BIOTISSUE HOLDINGS INC. $15,886.00 04/09/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
TTAX01-CR003 No dispute reported 06/30/2026 1246209697
Principal investigator 1 Incyte Corporation $2,349.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480474
Principal investigator 1 Incyte Corporation $889.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480481
Principal investigator 1 Incyte Corporation $1,532.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480487
Principal investigator 1 Incyte Corporation $6.36 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480491
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480500
Principal investigator 1 Incyte Corporation $25.75 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480533
Principal investigator 1 Incyte Corporation $48.54 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480538
Principal investigator 1 Incyte Corporation $6.18 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480544
Principal investigator 1 Incyte Corporation $103.05 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480551
Principal investigator 1 Incyte Corporation $74.04 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480578
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480584
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480590
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480595
Principal investigator 1 Incyte Corporation $2,048.40 03/12/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480238
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480224
Principal investigator 1 Incyte Corporation $1,972.20 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480234
Principal investigator 1 Incyte Corporation $1,419.00 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480255
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480344
Principal investigator 1 Incyte Corporation $54.76 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480348
Principal investigator 1 Incyte Corporation $4.24 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480369
Principal investigator 1 Incyte Corporation $34.35 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480373
Principal investigator 1 Incyte Corporation $541.60 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480377
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480385
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480409
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480413
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480419
Principal investigator 1 Incyte Corporation $1,208.70 02/10/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480246
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,506.25 02/01/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190295820
Principal investigator 1 Incyte Corporation $2,349.00 01/27/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480227
Principal investigator 1 Incyte Corporation $894.30 01/27/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480230
Principal investigator 1 Incyte Corporation $1,419.00 01/27/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480243
Principal investigator 1 Incyte Corporation $1,077.00 01/27/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480251
Principal investigator 1 Incyte Corporation $1,373.00 01/15/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480201
Principal investigator 1 Incyte Corporation $2,276.00 01/15/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480204
Principal investigator 1 Incyte Corporation $2,276.00 01/15/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480208
Principal investigator 1 Incyte Corporation $1,481.00 01/15/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480212
Principal investigator 1 Incyte Corporation $678.40 01/15/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480216
Principal investigator 1 Incyte Corporation $1,135.20 01/15/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480220
Principal investigator 1 Eli Lilly and Company $50,702.00 01/08/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187893030
Principal investigator 1 UCB SA $32,020.99 01/03/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1246656936
Principal investigator 1 Incyte Corporation $132.50 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480259
Principal investigator 1 Incyte Corporation $185.50 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480263
Principal investigator 1 Incyte Corporation $137.80 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480267
Principal investigator 1 Incyte Corporation $153.70 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480271
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480275
Principal investigator 1 Incyte Corporation $121.90 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480280
Principal investigator 1 Incyte Corporation $148.40 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480283
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480287
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480291
Principal investigator 1 Incyte Corporation $127.20 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480294
Principal investigator 1 Incyte Corporation $47.70 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480299
Principal investigator 1 Incyte Corporation $47.70 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480302
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480307
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480311
Principal investigator 1 Incyte Corporation $26.50 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480315
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480319
Principal investigator 1 Incyte Corporation $58.30 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480323
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480327
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480331
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480336
Principal investigator 1 Incyte Corporation $15.90 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480339
Principal investigator 1 Incyte Corporation $32.36 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480352
Principal investigator 1 Incyte Corporation $37.08 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480356
Principal investigator 1 Incyte Corporation $4.86 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480360
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480365
Principal investigator 1 Incyte Corporation $68.70 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480381
Principal investigator 1 Incyte Corporation $233.20 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480389
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480393
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480397
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480401
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480405
Principal investigator 1 Incyte Corporation $19.44 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480425
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480429
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480433
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480438
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480441
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480445
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480451
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480456
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480460
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480464
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240480469